EGFR and breast carcinoma: Breast cancer cell treatment with an EP4 agonist or synthetic PGE2 both stimulated epidermal growth factor receptor (EGFR) and increased tumor spheroid invadopodia, invasion, and extracellular matrix degradation by breast cancer cells (65).